left-arrow right-arrow pinterest facebook google_plus linkedin

NRG GY016

Status:

Recruiting | Phase II

Official Title:

Testing Whether the Combination of Two Immunotherapy Drugs Have Activity in Recurrent or Persistent Clear Cell Ovarian Cancer

Study Purpose:

To test any good and bad effects of the combination of two study drugs called MK-3475 (Pembrolizumab) and Epacadostat in treatment of clear cell ovarian cancer.

Interventions:

All patients will be given the study drugs MK-3475, also known as pembrolizumab (via IV) and epacadostat (oral pill daily).

After completion of treatment patients will be followed every three months for two years and then every six month for the next three years.

Key Participation Requirements:

Gender:

Female

Age:

19 years and older

Diagnosis:

Recurrent or persistent clear cell ovarian cancer

Eligibility:

Must have had at least one prior platinum-based chemotherapy for clear cell ovarian cancer.

Patients must sign an approved informed consent and authorization permitting release of personal health information.

Methodist Health System Trial Code:

NRG- GY016

For more information, visit the U.S. National Library of Medicine clinical trial database.

To learn more about this clinical trial please contact us today!